Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 4/20 | 0.34 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16629601 | 0.91 | CYP3A4 (0.35) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16629670 | 0.90 | CYP3A4 (0.36) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16629604 | 0.89 | GAA (0.39) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16629603 | 0.86 | KDM4E (0.40) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16629607 | 0.85 | CYP3A4 (0.37) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15783404 | 0.84 | MEN1 (0.46) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL17946228 | 0.83 | CYP3A4 (0.36) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16629614 | 0.82 | CCR1 (0.36) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16629703 | 0.82 | NPY5R (0.32) | HPGDALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL16629608 | 0.82 | MAPT (0.41) | HPGDMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | MERCK PATENT GMBH (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| WO-2015049022-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214942-A1 | TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES | KCNQ1, KCNH1, KCNQ2 | HPGD 1781/4885MEN1 1506/4885KMT2A 230/4885 |
| US-10407394-B2 | Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices | KCNQ1, KCNH1, KCNQ2 | HPGD 1781/4885MEN1 1506/4885KMT2A 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.